Evidence map›Paper›PMID 10668905›Full record

ReviewBrain pathology (Zurich, Switzerland)2000

Redox regulation of nuclear factor kappa B: therapeutic potential for attenuating inflammatory responses.

J W Christman, T S Blackwell, B H Juurlink

Open access · greenAbstract readReview
In one paragraph

Review in Brain pathology (Zurich, Switzerland), 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 147 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. The cysteine proteome.Free radical biology & medicine · 2015
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

J W ChristmanDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.
T S Blackwell
B H Juurlink
Nashville Oncology Associates · USPulmonary and Allergy Associates · USUniversity of Saskatchewan · CA

Funding

MOLECULAR REGULATION OF LUNG INFLAMMATION BY NF-KBR01HL061419 · NHLBI · VANDERBILT UNIVERSITY · PI BLACKWELL, TIMOTHY S · 1999 to 2006
$1.5M
NHLBI NIH HHS HL 61419
6 · The paper itself

Abstract

Nuclear factor kappa B (NF-kappaB) is a protein transcription factor that is required for maximal transcription of a wide array of pro-inflammatory mediators that are involved in the pathogenesis of stroke. The purpose of this review article is to describe what is known about the molecular biology of NF NF-kappaB and to review current understanding of the interaction between reactive oxygen species (ROS) in NF-kappaB. ROS seem to play a duel role by participating in the NF-kappaB activation cascade and by directly modulating DNA binding affinity. Exogenous and endogenous antioxidants are effective in blocking activation of NF-kappaB and preventing the consequences of pro-inflammatory gene expression. Phase II enzymes either directly or indirectly play a major in vivo role in minimizing oxidative stress by scavenging peroxides, peroxide breakdown products and dicarbonyls and in regeneration of lipid peroxidation chain-breaker, vitamin E. Dietary phase II enzyme inducers have been demonstrated to increase phase II enzyme activities in a variety of tissues. These data, together, suggest that phase II enzyme inducers could have therapeutic value for ameliorating inflammatory conditions.

Indexed as

AnimalsHumansInflammationNF-kappa BNF-kappa B

Identifiers

PMID10668905
PMCPMC8098183
OpenAlexW2085612389

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.